Yes, breast tissue produces its own estrogen. The fatty tissue in the breast contains an enzyme called aromatase that converts circulating androgens (hormones made by the adrenal glands) into estrogen. This local production is especially significant after menopause, when the ovaries stop making estrogen and the breast becomes one of the body’s primary estrogen-producing sites.
How the Breast Makes Estrogen
Estrogen production in the breast depends on aromatase, the rate-limiting enzyme in estrogen creation. Aromatase takes androgens already circulating in the blood, mainly androstenedione from the adrenal glands, and converts them into estrogen. About 80 to 90% of aromatase activity in breast tissue is found in immature fat cells called adipose fibroblasts, not in the mature fat cells themselves. Cells lining blood vessels in the breast and certain cells surrounding the milk ducts also express aromatase, though to a lesser degree.
The process works in steps. Aromatase first converts androstenedione into a weaker form of estrogen called estrone. A second enzyme then converts estrone into estradiol, the most biologically potent form of estrogen. Alternatively, aromatase can convert testosterone directly into estradiol. The result is a local supply of active estrogen right at the tissue level, independent of what the ovaries are doing.
Why This Matters More After Menopause
Before menopause, the ovaries are the dominant source of estradiol in the body, and the breast’s local production is a relatively minor contributor. After menopause, the picture changes dramatically. The ovaries essentially shut down estrogen production, and the adrenal glands produce only small amounts. The bulk of a postmenopausal woman’s estrogen comes from peripheral tissues like fat, skin, and breast tissue, where aromatase keeps working.
What makes this particularly important is that estrogen levels measured inside breast tissue are often much higher than estrogen levels in the blood. Studies measuring estradiol in breast tumor tissue from postmenopausal women have consistently found concentrations markedly above plasma levels. In some research, there was no correlation at all between blood estrogen and tissue estrogen, meaning a blood test doesn’t necessarily reflect what’s happening inside the breast. The estrogen produced locally acts right where it’s made, functioning more like a chemical signal between neighboring cells than a hormone traveling through the bloodstream.
What Triggers the Breast to Make More
Aromatase activity in the breast isn’t fixed. Several signals can ramp it up. Prostaglandin E2, an inflammatory molecule, significantly increases aromatase activity in breast stromal cells. This creates a feedback loop: inflammation boosts estrogen production, and estrogen can promote further cell growth and inflammation. Immune cells like macrophages and lymphocytes that infiltrate breast tissue also release signaling molecules called cytokines that stimulate aromatase. After menopause, there may even be a compensatory increase in peripheral aromatase activity in response to the drop in ovarian estrogen.
The Connection to Body Fat
Because aromatase lives primarily in fat tissue fibroblasts, the amount of adipose tissue in the breast directly influences local estrogen production. Women with higher body fat carry more of these fibroblasts, which means more aromatase and more estrogen conversion. This is one reason obesity is a well-established risk factor for postmenopausal breast cancer: more adipose tissue translates to a higher local estrogen supply feeding breast cells at a time when there’s no ovarian estrogen to regulate the system.
Local Estrogen and Breast Cancer
The breast’s ability to produce its own estrogen has direct implications for cancer. Roughly two-thirds of breast cancers are estrogen receptor-positive, meaning the tumor cells use estrogen as fuel. When estrogen binds to these receptors, it switches on genes involved in cell division, blood vessel formation, and resistance to cell death. In postmenopausal women, the estrogen driving this growth comes largely from local production rather than the bloodstream.
Research on mastectomy tissue has shown that aromatase activity varies across different areas of the same breast. The highest aromatase activity consistently appears in the quadrant containing the tumor, while quadrants with the lowest activity are never the ones where tumors develop. This doesn’t prove aromatase causes the cancer to form in that spot, but it strongly suggests a relationship between local estrogen concentration and tumor location.
Tumor cells themselves may actively shape their environment to boost estrogen supply. Breast cancer stromal cells communicate with surrounding fat tissue fibroblasts to increase aromatase expression, essentially recruiting nearby cells to produce more of the hormone the tumor needs. Some tumors even express their own aromatase, creating an internal estrogen source that can sustain growth even when systemic estrogen is suppressed by treatment.
How Treatments Target Local Production
Understanding that breast tissue makes its own estrogen led to the development of aromatase inhibitors, now a standard treatment for postmenopausal women with hormone receptor-positive breast cancer. These drugs block aromatase throughout the body, cutting off the local supply. In clinical studies, the three commonly used aromatase inhibitors reduced estradiol levels by 85 to 92%.
This approach differs fundamentally from older estrogen-blocking drugs like tamoxifen, which don’t reduce estrogen levels at all. Tamoxifen works by sitting in the estrogen receptor and preventing estrogen from binding. Aromatase inhibitors, by contrast, stop estrogen from being made in the first place, lowering both circulating and local tissue concentrations. For postmenopausal women whose estrogen comes almost entirely from peripheral conversion, this strategy is particularly effective because it targets the actual production machinery in the breast and other tissues.